# NCT03554083 (NCT03554083)

> Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03554083
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Mayo Clinic
- Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions: Atezolizumab; Cobimetinib; Tiragolumab; Vemurafenib
- Enrollment: 64
- Primary outcome: Pathologic Complete Response Rate (pCR)
- Primary outcome: Median Recurrence-free (RFS) Rate (Adjuvant Phase)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03554083